+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07582133

Long-term Safety and Effectiveness of HRS-5965 Capsules in Adults With Primary IgA Nephropathy

Led by Chengdu Suncadia Medicine Co., Ltd. · Updated on 2026-07-22

380

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety and tolerability of HRS-5965 capsules in patients with primary IgA nephropathy, a kidney condition. The study also aims to assess how well the drug reduces 24-hour urinary protein levels and delays the decline in kidney function measured by estimated glomerular filtration rate eGFR. Participants will receive HRS-5965 capsules as the experimental treatment. The study is an open-label, single-group trial where all participants will take the drug and be monitored over a period of 2 years. The focus is on assessing safety and efficacy outcomes during this time. During the study, participants will be closely monitored for adverse events and changes in kidney function through laboratory tests including 24-hour urine protein excretion, serum creatinine levels, and eGFR. The main outcomes measured include the incidence and severity of side effects and changes in kidney function markers over a 2-year period. Participants are expected to be involved throughout this duration until study completion.

CONDITIONS

Brief Title

A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy

Research Team

Y

Yanfang Zou

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here